Part,  Chapter, Paragraph

 1   II,     5.  2.  6|        countries. Acta Med Scand Suppl 460: 1-392.~Weijenberg MP,
 2   II,     5.  2.  7|      trends. Int J Epidemiol 18 (suppl):S20–S28.~Thom TJ, Epstein
 3   II,     5.  3.  2| oxfordjournals.org/content/vol18/suppl_3/index.dtl.~ ~ ~ ~
 4   II,     5.  3.  9|      20th century. Ann Oncol 14 (suppl 5):v128-v149.~ ~ESMO (2006):
 5   II,     5.  3.  9|      2007): Summary. Ann Onc 18 (Suppl 3): iii2–iii7.~ ~Micheli
 6   II,     5.  3.  9|         Eur J Public Health 13(3 Suppl):116-118.~ ~Parkin DM, Bray
 7   II,     5.  3.  9|        commentary. Ann Oncol 14 (suppl 5):v61-v118.~ ~Stewart BW,
 8   II,     5.  4.  8|         Res Clin Pract, 2000; 50(Suppl 1):35-47.~ ~K H (1998):
 9   II,     5.  5.  1|   project. Acta Psychiatr Scand (suppl 420): 21-27.~ ~Alonso J,
10   II,     5.  5.  1|        Acta Psychiatr Scand 109 (suppl 420):47-54.~ ~Alonso J,
11   II,     5.  5.  1|    ESEMeD). J Clin Psychiatry 68(suppl 2): 3-9.~ ~Berk M, Dodd
12   II,     5.  5.  1|      Survey. Br J Psychiatry 168(Suppl. 30):1730.~ ~Kovess-Masféty
13   II,     5.  5.  1|    studies. J Clin Psychiatry 68(Suppl 2):36-41.~ ~L . (2002).
14   II,     5.  5.  3|          Europe. Eur J Neurol 12 Suppl 1:1-27.~Andlin-Sobocki P,
15   II,     5.  5.  3|          Europe. Eur J Neurol 12 Suppl 1:74-77.~Andrews G, Sandersson
16   II,     5.  5.  3|    Clinical Psychiatry 2005, 66 (suppl. 10)~Knapp M, Romeo R, Beecham
17   II,     5.  5.  3|        Employment. Epilepsia 44 (suppl 6):49-50.~Barraclough BM (
18   II,     5.  5.  3|           a review. Epilepsia 38(suppl 11):S15-S19.~Olafsson E,
19   II,     5.  5.  3|    factors. Acta Neurol Scand 91(Suppl 161):71-76.~Boiko AN (1994):
20   II,     5.  5.  3| registersEDMUS. Ann Neurol 36(suppl):S136–S139.~Confavreux C,
21   II,     5.  5.  3|  research. Acta Neurol Scand 183(Suppl):37-40.~Nicoletti A, Lo
22   II,     5.  5.  3|          Europe. Eur J Neurol 12 Suppl 1:1-27.~Baldereschi M, Di
23   II,     5.  5.  3|      neurologica Scandinavica 42:Suppl 24:21-89.~Bundesamt für
24   II,     5.  5.  3|         s disease. Mov Disord 22 Suppl 17:S343-350.~Global Parkinson’
25   II,     5.  5.  3|          Europe. Eur J Neurol 12 Suppl 1:68-73.~Logroscino G (2005):
26   II,     5.  7.  7|         Am Soc Nephrol 2003;14(7 Suppl 2):S131-S138.~Chen J, Wildman
27   II,     5.  7.  7|          for therapy. Kidney Int Suppl 2005 Sep;(98):S25-S29.~Diez
28   II,     5.  7.  7|       for the future? Kidney Int Suppl 2004 Nov;(92):S7-10.~Gansevoort
29   II,     5.  7.  7|   general population. Kidney Int Suppl 2005 Apr;(94):S28-S35.~Garcia-Lopez
30   II,     5.  7.  7|          Dial Transplant 2001;16 Suppl 7:57-60~Lin J, Knight EL,
31   II,     5.  7.  7|         J Am Soc Nephrol 2002;13(Suppl 1):S37-S40.~McKenna AM,
32   II,     5.  7.  7|          Am J Kidney Dis 2006;47(Suppl 3):S1-S145.~National Kidney
33   II,     5.  7.  7|          Am J Kidney Dis 2003;41(suppl 3):S1-S92.~National Kidney
34   II,     5.  7.  7|          Am J Kidney Dis 2003;42(Suppl 3):S1-S202.~National Kidney
35   II,     5.  7.  7|          Am J Kidney Dis 2004;43(Suppl 1):S1-S290.~Obrador GT,
36   II,     5.  7.  7|         EPIRCE study. Kidney Int Suppl 2005 Dec;(99):S16-S19.~Pontoriero
37   II,     5.  9.  7|   dust-mite. Indoor Air. 2005;15 Suppl 10:33-9.~ ~European Community
38   II,     5.  9.  7|       Pulmonary Medicine 2006, 6(Suppl 1):S2 doi:10.1186/1471-2466-
39   II,     5.  9.  7|          Immunol. 2001 Jul;108(1 Suppl):S2-8.~ ~Torén K (2004):
40   II,     5. 12.  7|          countries. Addiction 96 Suppl 1:S19-33.~ ~Sauer P, Hansmann
41   II,     8.  2.  1|        50; doi:10.1093/eurpub/13.suppl_1.47~Walsh, P.N., Linehan,
42   II,     9.  1.  1|     Gynecol Reprod Biol 2003;111 Suppl 1:S78-87.~ ~Alran S, Sibony
43   II,     9.  1.  1|     Gynecol Reprod Biol 2003;111 Suppl 1:S45-52.~ ~Cans C, Guillem
44   II,     9.  1.  1|          Nicotine Tob Res 2004;6 Suppl 2:S125-40.~Cnattingius S,
45   II,     9.  1.  1|     Gynecol Reprod Biol 2003;111 Suppl 1:S5-S14.~ ~
46   II,     9.  3.  2|     Gynecol Reprod Biol 2003;111 Suppl 1:S78-87.~ ~Alran S, Sibony
47   II,     9.  3.  2|     Gynecol Reprod Biol 2003;111 Suppl 1:S45-52.~ ~Cans C, Guillem
48   II,     9.  3.  2|          Nicotine Tob Res 2004;6 Suppl 2:S125-40.~ ~De Galan-Roosen
49   II,     9.  3.  2|     Gynecol Reprod Biol 2003;111 Suppl 1:S5-S14.~ ~ ~
50  III,    10.  1.  3|       Alcohol Clin Exp Res 28(5) Suppl:48S-56S.~Blundell JE, King
51  III,    10.  1.  3|       Obes Relat Metab Disord 22 Suppl 2:S22-S29.~Bondy SJ (1996):
52  III,    10.  1.  3|          Sci Sports Exerc 31(11) Suppl 1:S534-541.~King NA (1998):
53  III,    10.  1.  3|         Bull Menninger Clin 58(2 Suppl A):A58-66.~McClelland GH,
54  III,    10.  1.  3|       aggression. J Stud Alcohol Suppl 11:53-61.~Miller NS, Giannini
55  III,    10.  1.  3|       Obes Relat Metab Disord 23 Suppl 8: S1-S107.~Rehm J, Ashley
56  III,    10.  1.  3|       aggression. J Stud Alcohol Suppl 11:78-88.~Thakker KD (1998):
57  III,    10.  1.  3|      dual pathway. Acta Paediatr Suppl 404:9-13.~Wood PD (1994):
58  III,    10.  2.  1|    review Am J Prev Med Jun;28(5 Suppl):280-7.~ ~Eurobarometer (
59  III,    10.  2.  1|         Oral Epidemiol. 2003; 31 Suppl 1:3-23.~ ~Petersen PE, Bourgeois
60  III,    10.  2.  1|       Sports and Exercise, 31(11 Suppl.):S526-S533.~ ~Sjöström
61  III,    10.  2.  1|   Related Metabolic Disorders 28(Suppl. 1):S71.~ ~Kapantais E,
62  III,    10.  2.  1|        health. Obesity Reviews 5(Suppl. 1):4-104.~ ~Lobstein T,
63  III,    10.  2.  1|       method. Eur J Clin Nutr 56 Suppl 2: S1-S3.~ ~European Commission (
64  III,    10.  4.  5|         Health Perspectives 108 (Suppl. 1):101-112~ ~MNR (2004)
65   IV,    11.  6.  5|           Health Affairs Jan-Jun(Suppl Web Exclusives): W5-97-W5-107.~ ~
66   IV,    13.  9    |          Europe. Eur J Neurol 12 Suppl 1:1-27.~EPC (Economic Policy